Norethindrone Acetate in the Medical Management of Adenomyosis

Pharmaceuticals

Ozgul Muneyyirci-Delale¹  Ashadeep Chandrareddy¹  Siddhi Mankame¹  Nanna Osei-Tutu¹ 

[1] Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA

关键词: norethindrone acetate;    adenomyosis;    dysmenorrhea;   

DOI  :  10.3390/ph5101120

来源: mdpi

【 摘 要 】

The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.